Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Guangdong Transtek Medical Electronics Co., Ltd (300562.SZ)
Zhongshan, CN
Guangdong Transtek Medical Electronics Co., Ltd, established in Zhongshan, China, in 2002, specializes in the development, manufacturing, and sale of various health-focused technological products within the Chinese market. The company provides a comprehensive range of offerings, including medically certified devices, internet-connected healthcare solutions, and smart wearable technology. Their product catalog features equipment for remote patient observation, blood pressure measurement tools, digital weighing scales, versatile wearable gadgets, and wireless audio devices.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.73% | -8.34% | -14.63% | -18.07% | -14.08% | -8.48% | -12.61% | +23.73% | -23.75% | +73.54% | +73.54% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-03 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+0.2% Q1'26: +3.8% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+35.7% ★ Q1'26: +36.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+11.1% Q1'26: +9.6% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+8.8% ★ Q1'26: +11.6% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+24.0% ★ Q1'26: +36.8% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.3% Q1'26: +4.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.42× ★ Q1'26: 0.36× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
883.67M
est: 881.38M (+0.3%)
|
1.34B
est: 1.31B (+2.0%)
|
1.80B
est.
|
1.82B
est: 2.55B (-28.5%)
|
884.26M
est: 998.21M (-11.4%)
|
1.07B
est: 998.21M (+6.7%)
|
983.98M
est: 1.19B (-17.1%)
|
986.21M
est: 1.53B (-35.7%)
|
1.93B
1.93B – 1.93B
+26.1% YoY
|
| EBITDA |
52.46M
est: 44.67M (+17.4%)
|
87.79M
est: 66.44M (+32.1%)
|
91.38M
est.
|
18.68M
est: 129.04M (-85.5%)
|
61.78M
est: 248.31M (-75.1%)
|
-17.32M
est: 248.31M (-107.0%)
|
86.09M
est: 295.27M (-70.8%)
|
112.60M
est: 381.33M (-70.5%)
|
480.83M
480.83M – 480.83M
+26.1% YoY
|
| EBIT |
38.42M
est: 22.54M (+70.5%)
|
73.08M
est: 33.52M (+118.0%)
|
46.10M
est.
|
415.4K
est: 65.10M (-99.4%)
|
37.91M
est: 211.47M (-82.1%)
|
-41.29M
est: 211.47M (-119.5%)
|
66.96M
est: 251.47M (-73.4%)
|
86.70M
est: 324.77M (-73.3%)
|
409.51M
409.51M – 409.51M
+26.1% YoY
|
| Net Income |
31.06M
est: 34.48M (-9.9%)
|
70.16M
est: 104.52M (-32.9%)
|
10.78M
est.
|
8.87M
est: 116.38M (-92.4%)
|
34.37M
est: 61.11M (-43.8%)
|
-32.36M
est: 61.11M (-153.0%)
|
61.36M
est: 60.56M (+1.3%)
|
82.00M
est: 78.39M (+4.6%)
|
97.92M
97.92M – 97.92M
+24.9% YoY
|
| SGA |
111.93M
est: 75.00M (+49.2%)
|
140.69M
est: 111.56M (+26.1%)
|
153.43M
est.
|
167.13M
est: 216.65M (-22.9%)
|
137.78M
est: 125.18M (+10.1%)
|
125.91M
est: 125.18M (+0.6%)
|
177.61M
est: 148.86M (+19.3%)
|
79.60M
est: 192.24M (-58.6%)
|
242.41M
242.41M – 242.41M
+26.1% YoY
|
| EPS |
0.16
est: 0.16 (+0.0%)
|
0.37
est: 0.49 (-23.7%)
|
0.05
est.
|
0.04
est: 0.54 (-92.6%)
|
0.16
est: 0.28 (-43.0%)
|
-0.15
est: 0.28 (-153.4%)
|
0.28
est: 0.28 (+0.0%)
|
0.38
est: 0.36 (+5.6%)
|
0.45
0.45 – 0.45
+25.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Linxiang Huang | Chief Financial Officer, Deputy GM, Secretary & Director | — | female |
| Wei Chao Pan | Chairman & GM | — | male |
| Xiaofei Wang | Accounting Supervisor | — | — |
| Zhigang Pan | Director & President | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300562.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
